• Press Office

    Posted in category News Release by Press Office on 18/06/2004

    ABPI welcomes Select Commitee inquiry into pharmaceutical industry

The announcement of the House of Commons Health Select Committee inquiry into the partnership between the pharmaceutical industry and those responsible for health policies, outcomes and future direction in the UK has been welcomed by the Association of the British Pharmaceutical Industry (ABPI).

 

​The ABPI notes that the Health Select Committee recognises the contribution made by the pharmaceutical industry to the health of the nation as well as the substantial economic benefits that it brings. The ABPI looks forward to co-operating fully with the committee as the inquiry progresses.

The wide-ranging inquiry will cover six main areas:

  • Drug innovation: The UK-based pharmaceutical industry is a world-leader in discovering and developing innovative new medicines, with 25 of the world's top 100 medicines originating in the UK. The industry invests nearly £10 million every single day in the search for new medicines.
  • Conduct of medical research: Medical research in the UK is conducted to the highest standards, and UK-based clinical trial work is highly regarded throughout the world.
  • Provision of drug information and promotion: The inquiry is particularly timely as the codes of conduct regulating the promotion and marketing of medicines are already being reviewed within the industry across Europe. As part of this, the ABPI is carrying out its own consultation and review of the ABPI Code of Practice, and will take into account the conclusions of the Health Select Committee.
  • Professional and patient education: The pharmaceutical industry carries out a large and extensive programme of education for GPs and other healthcare professionals that forms a vital element of their professional development.
  • Regulatory review of drug safety and efficacy: Companies have to demonstrate that each new medicine is safe and effective either to the UK regulatory authority, the Medicines and Healthcare Products Regulatory Agency, or the European body before it can gain a licence for use.
  • Product evaluation, including assessments of value for money: Medicines are an extremely cost-effective health intervention. Each prescription costs the NHS about £10, while a week's stay in hospital costs at least £1,500.
  • The industry in the UK makes a huge contribution to the health of the men, women and children of Britain as well as to the national economy. One of the key planks in achieving this success is to work in partnership with the Government and its various agencies and bodies, and we look forward to giving details of this activity to the Health Select Committee," said Vincent Lawton, President of the ABPI.

For further information, please contact: ABPI Press Office 020 7747 1410

 
 
Print this page icon Print this page
 
Please choose the subject of your enquiry from the list below:
 
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.